Impact of signs and symptoms on the prognosis of patients with HFmrEF.
HFmrEF
Heart failure
Signs
Symptoms
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
24 08 2023
24 08 2023
Historique:
received:
17
05
2023
accepted:
08
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Worsening of heart failure (HF) symptoms is the leading cause of medical contact and hospitalization of patients with mildly reduced ejection fraction (HFmrEF). The prognostic value of signs and symptoms for patients with HFmrEF is currently unclear. This study investigated the prognostic impact of signs and symptoms in HFmrEF patients. A Cox proportional risk regression model analyzed the relationship between the number of signs/symptoms and outcomes in 1691 hospitalized HFmrEF patients. Ten significant signs and symptoms were included. Patients were divided into three groups (A: ≤2, B: 3-5, C: ≥6 signs/symptoms). Stratified analysis on male and female patients was performed. The primary endpoint was all-cause mortality, and the secondary outcome was a composite of cardiovascular death and heart failure readmission (CV events) post-discharge. After a median follow-up of 33 months, all-cause mortality occurred in 457 patients and CV events occurred in 977 patients. Incidence of all-cause mortality was 20.7%, 32.3%* and 49.4%*† in group A, B and C of male patients, (*P < 0.05 vs. A, †P < 0.05 vs. B) and 18.8%, 33.6% and 55.8%* in group A, B and C of female patients. Incidence of CV events was 64.8%, 70.1%* and 87.5%* in group A, B and C of male patients, 61.9%, 75.3%, and 86.1%* in group A, B and C of female patients. Multivariate Cox regression showed older age, renal insufficiency, higher number of signs and symptoms (≥ 3, hazard ratio [HR] 1.317, 95% confidence interval [CI] 1.070-1.621, P = 0.009; ≥6, HR 1.982, 95% CI 1.402-2.801, P < 0.001), myocardial infarction, stroke, faster heart rate on admission, and diabetes were independently associated with all-cause mortality(all P < 0.05). Similarly, higher number of signs and symptoms (≥ 3, HR 1.271, 95% CI 1.119-1.443, P < 0.001; ≥6, HR 1.955, 95% CI 1.524-2.508, P < 0.001), older age, renal insufficiency, atrial fibrillation, and diabetes were independently associated with cardiovascular events (all P < 0.05). Higher number of symptoms and signs is associated with increased risk of all-cause mortality and CV events in HFmrEF patients. Our results highlight the prognostic importance of careful inquiry on HF symptoms and related physical examination in HFmrEF patients.
Sections du résumé
BACKGROUND
Worsening of heart failure (HF) symptoms is the leading cause of medical contact and hospitalization of patients with mildly reduced ejection fraction (HFmrEF). The prognostic value of signs and symptoms for patients with HFmrEF is currently unclear. This study investigated the prognostic impact of signs and symptoms in HFmrEF patients.
METHODS
A Cox proportional risk regression model analyzed the relationship between the number of signs/symptoms and outcomes in 1691 hospitalized HFmrEF patients. Ten significant signs and symptoms were included. Patients were divided into three groups (A: ≤2, B: 3-5, C: ≥6 signs/symptoms). Stratified analysis on male and female patients was performed. The primary endpoint was all-cause mortality, and the secondary outcome was a composite of cardiovascular death and heart failure readmission (CV events) post-discharge.
RESULTS
After a median follow-up of 33 months, all-cause mortality occurred in 457 patients and CV events occurred in 977 patients. Incidence of all-cause mortality was 20.7%, 32.3%* and 49.4%*† in group A, B and C of male patients, (*P < 0.05 vs. A, †P < 0.05 vs. B) and 18.8%, 33.6% and 55.8%* in group A, B and C of female patients. Incidence of CV events was 64.8%, 70.1%* and 87.5%* in group A, B and C of male patients, 61.9%, 75.3%, and 86.1%* in group A, B and C of female patients. Multivariate Cox regression showed older age, renal insufficiency, higher number of signs and symptoms (≥ 3, hazard ratio [HR] 1.317, 95% confidence interval [CI] 1.070-1.621, P = 0.009; ≥6, HR 1.982, 95% CI 1.402-2.801, P < 0.001), myocardial infarction, stroke, faster heart rate on admission, and diabetes were independently associated with all-cause mortality(all P < 0.05). Similarly, higher number of signs and symptoms (≥ 3, HR 1.271, 95% CI 1.119-1.443, P < 0.001; ≥6, HR 1.955, 95% CI 1.524-2.508, P < 0.001), older age, renal insufficiency, atrial fibrillation, and diabetes were independently associated with cardiovascular events (all P < 0.05).
CONCLUSIONS
Higher number of symptoms and signs is associated with increased risk of all-cause mortality and CV events in HFmrEF patients. Our results highlight the prognostic importance of careful inquiry on HF symptoms and related physical examination in HFmrEF patients.
Identifiants
pubmed: 37620764
doi: 10.1186/s12872-023-03436-z
pii: 10.1186/s12872-023-03436-z
pmc: PMC10464266
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
420Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
N Engl J Med. 2001 Aug 23;345(8):574-81
pubmed: 11529211
J Card Fail. 2017 Dec;23(12):868-875
pubmed: 29029965
Eur J Cardiovasc Nurs. 2009 Jun;8(2):91-6
pubmed: 18715830
Heart Fail Rev. 2002 Jan;7(1):9-16
pubmed: 11790919
Eur J Heart Fail. 2007 Jun-Jul;9(6-7):702-8
pubmed: 17188930
Circulation. 2019 Oct 22;140(17):1369-1379
pubmed: 31510768
Heart Lung. 1997 May-Jun;26(3):169-76
pubmed: 9176684
JACC Heart Fail. 2018 Jul;6(7):543-551
pubmed: 29885957
JACC Heart Fail. 2021 May;9(5):386-397
pubmed: 33714741
Eur J Heart Fail. 2007 Jan;9(1):83-91
pubmed: 17188020
Circ Heart Fail. 2021 Oct;14(10):e008406
pubmed: 34455858
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421
pubmed: 35379503
Eur J Cardiovasc Nurs. 2002 Dec;1(4):223-5
pubmed: 14622651
Arch Intern Med. 2007 Dec 10;167(22):2503-8
pubmed: 18071174
ESC Heart Fail. 2022 Feb;9(1):363-372
pubmed: 34889076
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
ESC Heart Fail. 2022 Oct;9(5):3124-3138
pubmed: 35751458
Congest Heart Fail. 2007 Mar-Apr;13(2):99-104
pubmed: 17392614
Am Heart J. 2000 Dec;140(6):840-7
pubmed: 11099986
ESC Heart Fail. 2014 Sep;1(1):4-25
pubmed: 28834669
JACC Heart Fail. 2014 Feb;2(1):15-23
pubmed: 24622114